Congress, the FDA, and the fair development of new medications for children.
McKinney
Ross E
RE
Department of Pediatrics, Division of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710, USA. ross.mckinney@duke.edu
D000328:Adult; D002648:Child; D003226:Congresses as Topic; D017277:Drug Approval / Q000331:legislation & jurisprudence; D015195:Drug Design; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D004348:Drug Labeling / Q000331:legislation & jurisprudence / Q000639:trends; D006801:Humans; D007880:Legislation, Drug / Q000639:trends; D009965:Orphan Drug Production / Q000191:economics / Q000331:legislation & jurisprudence; D004364:Pharmaceutical Preparations / Q000191:economics*; D014481:United States; D014486:United States Food and Drug Administration
D004364:Pharmaceutical Preparations